955 related articles for article (PubMed ID: 29286103)
21. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
23. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
[TBL] [Abstract][Full Text] [Related]
24. [Detection of WT1 gene in acute myeloid leukemia children by real-time fluorescent quantitative RT-PCR and its clinical significance].
Zhang R; Sun HQ; Li G; Bai FY; Yang Y; Jing Q; Shi YJ; Yang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):959-63. PubMed ID: 21867623
[TBL] [Abstract][Full Text] [Related]
25. The Wilms Tumor-1 (WT1) rs2234593 variant is a prognostic factor in normal karyotype acute myeloid leukemia.
Niavarani A; Horswell S; Sadri R; Bonnet D
Ann Hematol; 2016 Jan; 95(2):179-90. PubMed ID: 26499507
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
27. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.
Herold T; Metzeler KH; Vosberg S; Hartmann L; Jurinovic V; Opatz S; Konstandin NP; Schneider S; Zellmeier E; Ksienzyk B; Graf A; Krebs S; Blum H; Cristina Sauerland M; Büchner T; Berdel WE; Wörmann BJ; Mansmann U; Hiddemann W; Bohlander SK; Spiekermann K; Greif PA
Genes Chromosomes Cancer; 2017 Jan; 56(1):75-86. PubMed ID: 27636548
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of WT-1 and Survivin Gene Expression in Acute Myeloid Leukemia Patients.
Adnan-Awad S; Meligui YME; Salem SE; Salaheldin O; Ayoub MA; Kamel MM
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969080
[TBL] [Abstract][Full Text] [Related]
31. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
[TBL] [Abstract][Full Text] [Related]
32. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
33. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
34. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia.
Spassov BV; Stoimenov AS; Balatzenko GN; Genova ML; Peichev DB; Konstantinov SM
Hematology; 2011 Jan; 16(1):37-42. PubMed ID: 21269566
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
36. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
37. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
38. Overexpressed WT1 exhibits a specific immunophenotype in intermediate and poor cytogenetic risk acute myeloid leukemia.
Wang XR; Chang Y; Yuan XY; Wang YZ; Qin YZ; Ruan GR; Lai YY; Liu YR
Ann Hematol; 2020 Feb; 99(2):215-221. PubMed ID: 31900500
[TBL] [Abstract][Full Text] [Related]
39. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
40. Reduction in WT1 gene expression during early treatment predicts the outcome in patients with acute myeloid leukemia.
Andersson C; Li X; Lorenz F; Golovleva I; Wahlin A; Li A
Diagn Mol Pathol; 2012 Dec; 21(4):225-33. PubMed ID: 23111196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
